HN2000000078A - Amidas sustituidas del acido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporacion de adenosina - Google Patents

Amidas sustituidas del acido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporacion de adenosina

Info

Publication number
HN2000000078A
HN2000000078A HN2000000078A HN2000000078A HN2000000078A HN 2000000078 A HN2000000078 A HN 2000000078A HN 2000000078 A HN2000000078 A HN 2000000078A HN 2000000078 A HN2000000078 A HN 2000000078A HN 2000000078 A HN2000000078 A HN 2000000078A
Authority
HN
Honduras
Prior art keywords
amidas
acid
fenilciclohexanocarboxilico
inhibitors
replaced
Prior art date
Application number
HN2000000078A
Other languages
English (en)
Inventor
Bischoff Erwin
Jananichen Jan
Keldenich Jorg
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HN2000000078A publication Critical patent/HN2000000078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

LA PRESENTE INVENCION SE REFIERE A AMIDAS SUSTITUIDAS DEL ACIDO FENILCICLOHEXANOCARBOXILICO, A PROCEDIMIENTOS PARA SU OBTENCION Y A SU USO EN MEDICAMENTOS, ESPECIALMENTE PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, POR EJEMPLO EL TRATAMIENTO AGUDO Y CRONICO DE ENFERMEDADES ISQUEMICAS.
HN2000000078A 1999-05-29 2000-05-17 Amidas sustituidas del acido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporacion de adenosina HN2000000078A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924819A DE19924819A1 (de) 1999-05-29 1999-05-29 Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren)

Publications (1)

Publication Number Publication Date
HN2000000078A true HN2000000078A (es) 2001-02-02

Family

ID=7909713

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2000000078A HN2000000078A (es) 1999-05-29 2000-05-17 Amidas sustituidas del acido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporacion de adenosina

Country Status (25)

Country Link
US (1) US6984642B1 (es)
EP (1) EP1187812B1 (es)
JP (1) JP2003500474A (es)
KR (1) KR20020000814A (es)
CN (1) CN1165526C (es)
AR (1) AR029639A1 (es)
AT (1) ATE303995T1 (es)
AU (1) AU766140B2 (es)
BR (1) BR0011049A (es)
CA (1) CA2375188A1 (es)
CO (1) CO5170503A1 (es)
DE (2) DE19924819A1 (es)
DK (1) DK1187812T3 (es)
ES (1) ES2248071T3 (es)
GT (1) GT200000085A (es)
HK (1) HK1047107B (es)
HN (1) HN2000000078A (es)
IL (1) IL146231A0 (es)
MX (1) MXPA01012240A (es)
PE (1) PE20010132A1 (es)
PL (1) PL365960A1 (es)
TR (1) TR200103398T2 (es)
UY (1) UY26179A1 (es)
WO (1) WO2000073274A2 (es)
ZA (1) ZA200108894B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10150310A1 (de) * 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
KR100762858B1 (ko) * 2005-03-07 2007-10-02 김기완 Ｐｅ시트를 이용한 저수조의 방수 공법
KR100762857B1 (ko) * 2005-03-07 2007-10-02 김기완 Ｐｅ시트를 이용한 저수조의 방수 공법
KR100745024B1 (ko) * 2005-05-09 2007-08-01 김준 거푸집 수평조절장치
WO2010009068A2 (en) * 2008-07-16 2010-01-21 Bristol-Myers Squibb Company Cyclohexenyl modulators of chemokine receptor activity
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322707T2 (de) * 1992-07-31 1999-08-19 Bristol Myers Squibb Co Diphenyl Oxazole-, Thiazole- und Imidazole-Derivate als Inhibitoren der Wiederaufnahme des Adenosins
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
CZ65398A3 (cs) * 1995-09-22 1998-07-15 Sumitomo Chemical Company, Limited Derivát pyrazinu-2-on, způsob kontroly nechtěných plevelů a použití derivátu
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle

Also Published As

Publication number Publication date
AR029639A1 (es) 2003-07-10
CA2375188A1 (en) 2000-12-07
GT200000085A (es) 2001-11-17
KR20020000814A (ko) 2002-01-05
HK1047107A1 (en) 2003-02-07
CN1353693A (zh) 2002-06-12
JP2003500474A (ja) 2003-01-07
EP1187812A2 (de) 2002-03-20
IL146231A0 (en) 2002-07-25
ES2248071T3 (es) 2006-03-16
US6984642B1 (en) 2006-01-10
TR200103398T2 (tr) 2002-03-21
BR0011049A (pt) 2002-03-19
ATE303995T1 (de) 2005-09-15
AU766140B2 (en) 2003-10-09
DK1187812T3 (da) 2005-12-12
PE20010132A1 (es) 2001-04-12
WO2000073274A3 (de) 2001-04-19
MXPA01012240A (es) 2002-08-12
WO2000073274A2 (de) 2000-12-07
AU4405700A (en) 2000-12-18
EP1187812B1 (de) 2005-09-07
HK1047107B (zh) 2005-05-20
DE50011122D1 (de) 2005-10-13
ZA200108894B (en) 2003-01-29
DE19924819A1 (de) 2000-11-30
CO5170503A1 (es) 2002-06-27
PL365960A1 (en) 2005-01-24
UY26179A1 (es) 2000-12-29
CN1165526C (zh) 2004-09-08

Similar Documents

Publication Publication Date Title
HN1999000124A (es) Derivados de pirazol substituido.
CR9749A (es) Derivados de xantina como agonistas de hm74a selectivos
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
DOP2006000235A (es) Derivados de acidos dicarboxilicos y su uso
HN2009001131A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolinas sustituidas de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
BR0318383A (pt) derivados de pirazoloisoquinolina como inibidores de cinase
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
ATE453642T1 (de) Substituierte phenylaminopyrimidine
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
UY29264A1 (es) Tiazolidinonas metasustituidas, su preparación y su uso como medicamento
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
AR053775A1 (es) Nonadepsipeptidos acilados ii
UY28313A1 (es) Nonadepsipeptidos acilados
HN2006007774A (es) Imidazoles sustituidos con heterociclilamida
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
UY28115A1 (es) Derivados del acido isoftalico
HN2000000078A (es) Amidas sustituidas del acido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporacion de adenosina
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
UY27733A1 (es) Derivados de ciclopenteno.
PA8491201A1 (es) Procedimiento para preparar secretagogos de hormonas del crecimiento.
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b